What are the 2026 AHA/ACC guidelines for the diagnosis and management of acute pulmonary embolism?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

2026 AHA/ACC Pulmonary Embolism Guidelines

Risk Stratification Framework

The 2026 AHA/ACC guideline introduces new "AHA/ACC Acute Pulmonary Embolism Clinical Categories" that enhance severity classification beyond the traditional ESC framework. 1

High-Risk (Massive) PE

  • Sustained systolic blood pressure < 90 mmHg for ≥ 15 minutes, need for vasopressor support, obstructive shock, or cardiac arrest. 21
  • Immediate mortality risk without reperfusion is the dominant concern. 2

Intermediate-Risk (Submassive) PE

  • Requires hemodynamic stability PLUS both:
    • Right ventricular dysfunction on imaging (RV/LV ratio > 0.9 on CTPA or echocardiography) 21
    • Elevated cardiac biomarkers (troponin or BNP/NT-proBNP) 21
  • The National Early Warning Score (NEWS) ≥ 7 identifies intermediate-risk patients at highest mortality risk (24% vs 1% with NEWS < 7). 3

Low-Risk PE

  • PESI class I–II (score ≤ 85) or simplified PESI = 0, absence of RV dysfunction, and normal cardiac biomarkers. 21
  • These patients are eligible for early discharge with outpatient management. 2

Immediate Anticoagulation (All Risk Categories)

Administer weight-adjusted unfractionated heparin (80 IU/kg bolus, then 18 IU/kg/h infusion) immediately when PE is suspected, without waiting for imaging confirmation. 21

  • Do not delay anticoagulation while diagnostic workup is in progress in patients with high or intermediate clinical probability. 42
  • Target aPTT 1.5–2.5 × control (approximately 45–75 seconds); check aPTT 4–6 hours after bolus, then 6–10 hours after dose adjustments, then daily once therapeutic. 2

Management by Risk Category

High-Risk PE: Immediate Reperfusion Required

Systemic thrombolysis is first-line therapy and should be administered immediately; it reduces mortality by approximately 20 deaths per 1,000 treated. 21

Thrombolytic Regimens 2

Agent Dose
Alteplase (rtPA) 100 mg infused over 2 hours
Streptokinase 250,000 U over 20 min, then 100,000 U/h × 24 h
Urokinase 4,400 IU/kg over 10 min, then 4,400 IU/kg/h × 12 h

Alternative Reperfusion When Thrombolysis Contraindicated or Fails

  • Surgical pulmonary embolectomy is indicated for absolute contraindications to thrombolysis (active bleeding, recent intracranial hemorrhage, recent neurosurgery) or thrombolysis failure; contemporary mortality is approximately 12%, with meta-analysis showing 22.6% mortality versus 41.8% with other strategies (OR 0.44, p = 0.009). 21

  • Catheter-directed therapy should be considered when surgery is unsuitable. 21

  • ECMO combined with surgical embolectomy or catheter-directed therapy may be employed in refractory circulatory collapse; reported survival to discharge is 84.6–93%. 2

Hemodynamic Support

  • Norepinephrine and/or dobutamine for vasopressor support. 2
  • Stop unfractionated heparin before thrombolysis, then resume maintenance dosing afterward. 2

Intermediate-Risk PE: Intensive Monitoring with Rescue Thrombolysis

Routine systemic thrombolysis is NOT recommended for hemodynamically stable intermediate-risk PE because major bleeding risk (approximately 65 per 1,000 treated) outweighs mortality benefit. 421

  • Meta-analysis demonstrates mortality 2.29% with thrombolysis versus 4.03% with anticoagulation alone (OR 0.57), but major bleeding 9.46% versus 3.75% (OR 2.70). 2

Rescue Thrombolysis Triggers

Administer rescue systemic thrombolysis immediately if ANY of the following occur: 421

  • Worsening hypotension (systolic BP trending toward < 90 mmHg)
  • Persistent or worsening tachycardia
  • Rising cardiac biomarkers on serial measurement
  • Progressive RV dysfunction on repeat imaging
  • Worsening hypoxia or respiratory distress

Risk Refinement with NEWS Score

  • Within ESC intermediate-high and high-risk groups, NEWS ≥ 7 identifies patients with 24% 30-day mortality versus 1% with NEWS < 7. 3
  • Patients with NEWS ≥ 7 who received advanced therapy had lower mortality (18% vs 39%), though not statistically significant. 3

Multidisciplinary Decision-Making

  • Activate Pulmonary Embolism Response Teams (PERTs) for intermediate-high risk cases to enable real-time, cross-specialty decision-making (cardiology, pulmonology, interventional radiology, cardiac surgery). 21

Low-Risk PE: Anticoagulation Alone

Anticoagulation alone is sufficient; early discharge with reliable outpatient follow-up is appropriate when vital signs are stable, biomarkers are negative, RV function is normal, and PESI/sPESI is low. 421

Anticoagulation Strategy for Stable Patients

Preferred Oral Agents

Direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban) are preferred over warfarin for all eligible patients; they provide comparable efficacy with lower major bleeding risk. 421

Parenteral Therapy in Stable Patients

Low-molecular-weight heparin (LMWH) or fondaparinux are preferred over unfractionated heparin in hemodynamically stable patients. 421

Absolute Contraindications to DOACs 421

  • Severe renal impairment (creatinine clearance < 15–30 mL/min, depending on agent)
  • Antiphospholipid antibody syndrome (requires indefinite warfarin)
  • Pregnancy or lactation

Warfarin Initiation When DOACs Contraindicated

  • Initial dose 5–10 mg daily for 2 days. 2
  • Overlap with parenteral anticoagulation until INR ≥ 2.5 (target 2.0–3.0) for ≥ 24 hours. 421
  • Discontinue heparin 5 days after warfarin start if INR ≥ 2.0. 2
  • Monitor INR every 1–2 days initially. 2

Duration of Anticoagulation

All patients with PE require therapeutic anticoagulation for a minimum of > 3 months. 4421

Discontinue After 3 Months

Stop anticoagulation after 3 months if the PE was provoked by a major transient/reversible risk factor (surgery, trauma, prolonged immobilization). 4421

Continue Indefinitely

Continue indefinitely for: 4421

  • Recurrent VTE not related to a transient factor
  • Unprovoked PE (after individualized bleeding-risk assessment)
  • Antiphospholipid antibody syndrome (requires warfarin)

Ongoing Monitoring

Regularly reassess drug tolerance, adherence, hepatic/renal function, and bleeding risk during extended therapy. 4421

Inferior Vena Cava (IVC) Filters

Routine use of IVC filters is NOT recommended because they do not reduce mortality and increase long-term DVT risk; the PREPIC trial showed no mortality benefit. 421

Limited Indications 421

  • Acute PE with absolute contraindication to anticoagulation (active bleeding, recent intracranial hemorrhage, recent neurosurgery)
  • Recurrent PE despite documented therapeutic anticoagulation

Use retrievable filters whenever possible and remove them once anticoagulation can be safely resumed. 2

Pregnancy-Specific Management

Therapeutic fixed-dose LMWH (dose adjusted for early-pregnancy weight) is the anticoagulant of choice for hemodynamically stable pregnant patients. 4421

NOACs are absolutely contraindicated during pregnancy and lactation. 4421

Neuraxial Anesthesia Precautions 442

  • Avoid spinal/epidural needle insertion within 24 hours of the last LMWH dose
  • Do not administer LMWH within 4 hours after epidural catheter removal

Diagnostic Strategy

Clinical Probability Assessment

Base the diagnostic strategy on clinical probability using either clinical judgment or a validated prediction rule (Wells score). 42

D-Dimer Testing

Measure D-dimer in plasma (preferably with a highly sensitive assay) in outpatients/emergency department patients with low or intermediate clinical probability. 42

  • Use age-adjusted D-dimer cutoff (age × 10 µg/L for patients > 50 years) to improve specificity in older patients. 2
  • Do NOT measure D-dimer in patients with high clinical probability; a normal result does not safely exclude PE. 421

Imaging

CTPA is the first-line imaging test for the majority of patients. 2

  • Accept the diagnosis of PE if CTPA shows a segmental or more proximal filling defect in a patient with intermediate or high clinical probability. 42
  • Reject the diagnosis of PE (without further testing) if CTPA is normal in a patient with low or intermediate clinical probability. 42
  • If CTPA reports isolated subsegmental PE, obtain a second radiology opinion because false-positives are common and unnecessary anticoagulation may cause harm. 2

Do NOT perform CT venography as an adjunct to CTPA. 42

Do NOT perform MRA to rule out PE. 42

A normal ventilation-perfusion (V/Q) scan excludes PE. 42

Demonstration of a proximal DVT on compression ultrasonography confirms venous thromboembolism in a patient with suspected PE. 42

Follow-Up Protocol

Re-evaluate all patients 3–6 months after acute PE to assess recovery, detect complications, and determine anticoagulation duration. 4421

Refer symptomatic patients with mismatched perfusion defects on V/Q scan beyond 3 months to a chronic thromboembolic pulmonary hypertension (CTEPH) expert center; consider echocardiography, natriuretic peptide, and cardiopulmonary exercise testing in the referral decision. 442

Implement an integrated care model to ensure seamless transition from hospital to ambulatory care. 442

Critical Pitfalls to Avoid

  • Do NOT delay anticoagulation while awaiting imaging in patients with high or intermediate clinical probability. 421
  • Do NOT measure D-dimer in high-probability patients; a normal result does not safely exclude PE. 421
  • Do NOT give routine systemic thrombolysis to hemodynamically stable intermediate-risk PE patients; bleeding risk (approximately 65 per 1,000) exceeds mortality benefit. 421
  • Do NOT place IVC filters routinely; they increase thrombosis risk without mortality benefit. 421
  • Do NOT perform CT venography as an adjunct to CTPA. 42
  • Do NOT delay thrombolysis for imaging in patients in extremis; clinical probability plus bedside echocardiography is sufficient. 2

Disparities in PE Care

The 2026 AHA/ACC guideline emphasizes that disparities exist in PE diagnosis, treatment strategies, and outcomes associated with race, ethnicity, sex, and socioeconomic status, which correlate with poorer downstream outcomes including recurrent PE, CTEPH, and mortality. 5

  • Incidence of PE is higher among certain racial groups, reproductive-age women compared with age-matched men, and transgender people taking estrogen hormones. 5
  • Approaches to create equitable PE care and address knowledge gaps in the literature are needed. 5

References

2
Guideline

Risk‑Adapted Management of Pulmonary Embolism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the recommended anticoagulant doses for treating acute pulmonary embolism in adults, including adjustments for renal impairment and bleeding risk?
In a 20‑year‑old previously healthy female with two days of fever, cough, congestion, sore throat, left‑lower‑chest pain, normal vital signs, normal chest X‑ray and a Wells score of 1.5 (low pre‑test probability), what is the next step to safely rule out pulmonary embolism?
Can pulmonary embolism cause a hypertensive emergency?
What is the appropriate management of acute pulmonary embolism?
Can a pulmonary embolism involving two segmental pulmonary arteries cause severe pulmonary hypertension?
Is the local anesthetic injected directly into the incision (skin and subcutaneous tissue) during the procedure?
What is the recommended emergency department protocol for managing sepsis?
When are beta‑blockers indicated in aortic stenosis and aortic regurgitation, and how should they be started and titrated?
How should a child with Flexabenz (cyclobenzaprine) poisoning be managed?
What are the treatment options for laryngeal carcinoma?
Patient experiencing pain that began five weeks after placement of polydioxanone (PDO) threads; what is the likely cause and how should it be treated?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.